The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...
One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...
By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...
The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...
Q4 2024 Management View CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback